Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant sars-cov-2 vaccine (cho cell) lyb001
- Development stage
- Phase 3
- Lead developer
- Yantai Patronus Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
LYB001 is an innovative virus-like particle (VLP)-based recombinant protein COVID-19 vaccine. It displays a repetitive array of the receptor-binding domain (RBD) from the spike glycoprotein of wild-type SARS-CoV-2 on the surface of a VLP vector, produced using Covalink plug-and-display protein binding technology. The RBD is expressed in CHO cells and conjugated to a VLP vector expressed in E. coli, then adsorbed onto aluminum hydroxide adjuvant for administration. LYB001 elicits robust neutralizing antibody responses against both prototype SARS-CoV-2 and Omicron BA.4/5 variants, as well as strong T-cell responses to RBD-specific peptide pools. It has demonstrated high immunogenicity and a favorable safety profile as a heterologous booster in adults previously vaccinated with inactivated COVID vaccines[1][2][3][5][8]. Developed by Yantai Patronus Biotech, it is currently undergoing phase 2/3 clinical trials for COVID-19 prevention[6].
- Other names
- LYB001LYB-001LYB 001recombinant sars-cov-2 vaccine (cho cell) lyb001
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on recombinant sars-cov-2 vaccine (cho cell) lyb001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant sars-cov-2 vaccine (cho cell) lyb001.